1. Editorial: biologic therapies for primary sclerosing cholangitis—more disappointment than promise? Authors' reply. Issue 5 (9th August 2018) Authors: Tse, C. S.; Loftus, E. V.; Raffals, L. E.; Gossard, A. A.; Lightner, A. L. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 5(2018) Page Start: 578 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. Issue 2 (28th May 2018) Authors: Tse, C. S.; Loftus, E. V.; Raffals, L. E.; Gossard, A. A.; Lightner, A. L. Journal: Alimentary pharmacology & therapeutics Issue: Volume 48:Issue 2(2018) Page Start: 190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. Issue 1 (27th October 2014) Authors: De Felice, K. M.; Novotna, M.; Enders, F. T.; Faubion, W. A.; Tremaine, W. J.; Kantarci, O. H.; Raffals, L. E. Journal: Alimentary pharmacology & therapeutics Issue: Volume 41:Issue 1(2015) Page Start: 99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations. Issue 5 (18th December 2017) Authors: Lightner, A. L.; McKenna, N. P.; Tse, C. S.; Raffals, L. E.; Loftus, E. V.; Mathis, K. L. Journal: Alimentary pharmacology & therapeutics Issue: Volume 47:Issue 5(2018) Page Start: 573 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗